Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study assesses the efficacy and safety of Viokase® 16 for the correction of steatorrhea
(malabsorption of dietary fats) in patients with a history of exocrine pancreatic
insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatectomy. This study is
sponsored by Aptalis Pharma (formerly Axcan).